The value of undiscovered pharmaceuticals in tropical forests

Economic Botany volume 49, pages223–228(1995)Cite this article

Abstract

Previous estimates of the potential value of higher plants in tropical forests for Pharmaceuticals are too high because analysts mistakenly used gross revenues to value drugs instead of net revenues. Correcting this error, we estimate each new drug is worth an average $94 million to a private drug company and $449 million to society as a whole. Given recent experience searching for new drugs, we estimate that the higher plants in the world’s tropical forests contain about 375 potential pharmaceuticals of which 48 (about one in eight) have already been discovered. Multiplying these values by the number of potential new drugs suggests that a complete collection and screening of all tropical plant species should be worth about $3–4 billion to a private pharmaceutical company and as much as $147 billion to society as a whole.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Literature Cited

  1. Abelson, P. H. 1990. Medicine from plants. Science 247:513.

    PubMed  Article  CAS  Google Scholar 

  2. Balick, M., and R. Mendelsohn. 1992. The economic value of traditional medicine from tropical rain forests. Conservation Biology 6:128–139.

    Article  Google Scholar 

  3. DiMasi, J., N. Bryant, and L. Lasagna. 1991. New drug development in the United States, 1963–1990. Clinical Pharmaceutical Therapeutics 50:471–486.

    CAS  Google Scholar 

  4. Duke, J. 1987. Economic impact of botanicals. Pages 1–5in L. Grant, ed., Proceedings of second national herb growing and marketing conference. Purdue Research Foundation, W. Lafayette, IN.

    Google Scholar 

  5. Farnsworth, N., and D. Soejarto. 1985. Potential consequences of plant extinction in the United States on the current and future availability of prescription drugs. Economic Botany 39:231–240.

    Google Scholar 

  6. Gentry, A. 1993. Tropical forest biodiversity and the potential for new medicinal plants. Pages 13–24in A. D. Kinghornand M. F. Balandrin, eds., Human medicinal agents from plants. American Chemical Society, Washington, D.C.

    Google Scholar 

  7. Grabowski, M., and J. Vernon. 1990. A new look at the returns and risks to pharmaceutical R&D. Management Science 36:804–821.

    Article  Google Scholar 

  8. Grimes.A., S. Loomis, P. Jahnige, M. Burnham, K. Onthank, R. Alarcon, W. Palacios Cuenca, C. C. Martinez, D. Neill, M. Balick, B. Bennett, and R. Mendelsohn. 1994. The value of tropical forests: a study of nontimber forest products in the primary forest of the Upper Napo Province, Ecuador. Ambio 23:405–410.

    Google Scholar 

  9. Hansen, R. 1979. The pharmaceutical development process: estimates of development costs and times and the effect of proposed regulatory changes. Pages 151–191in R. Chien, ed., Issues in pharmaceutical economics. DC Heath Co., Lexington, MA.

    Google Scholar 

  10. Maille, P., and R. Mendelsohn. 1993. Valuing ecotourism in Madagascar. Journal of Environmental Management 39:213–218.

    Article  Google Scholar 

  11. OTA (Office of Technology Assessment). 1993. Pharmaceutical R&D: costs, risks and rewards, U.S. Government Printing Office, Washington, D.C.

    Google Scholar 

  12. Oldfield, M. L. 1989. The value of conserving genetic resources. Sinauer Associates, Sunderland, MA.

    Google Scholar 

  13. Pearce, D., and S. Puroshothaman. 1993. Protecting biological diversity: the economic value of pharmaceutical plants. CSERGE, University College, London.

    Google Scholar 

  14. Peters, C, A. Gentry, and R. Mendelsohn. 1989. Valuation of an Amazonian rainforest. Nature 339: 655–656.

    Article  Google Scholar 

  15. Reid, W. V. 1993. A new lease on life. Pages 1–52in W. V. Reid, S. A. Laird, C. A. Meyer, R. Gamez, A. Sittenfeld, D. H. Janzen, M. A. Gollin,and C. Juma, eds., Biodiversity prospecting: using genetic resources for sustainable development. World Resources Institute, Washington, D. C.

    Google Scholar 

  16. Sharma, N., R. Rowe, K. Openshaw, and M. Jacobson. 1992. World forests in perspective. Pages 17–31in N. Sharma, ed., Managing the world’s forests. Kendall/Hunt Publishing Company, Dubuque, IA.

    Google Scholar 

  17. Soejarto, D., and N. Farnsworth. 1989. Tropical rain forests: potential source of new drugs? Perspectives in Biology and Medicine 32:244–256.

    PubMed  CAS  Google Scholar 

  18. Tobias, D., and R. Mendelsohn. 1991. Valuing ecotourism at a tropical rain forest preserve. Ambio 20:91–93.

    Google Scholar 

  19. World Conservation Monitoring Centre. 1992. Global biodiversity: status of the earth’s living resources. Chapman and Hall, London.

    Google Scholar 

Download references

Author information

Affiliations

  1. Yale School of Forestry and Environmental Studies, 360 Prospect Street, 06511, New Haven, CT, USA

    Robert Mendelsohn

  2. Institute of Economic Botany, The New York Botanical Garden, 10458, Bronx, NY, USA

    Michael J. Balick

Authors
  1. Robert Mendelsohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Balick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Mendelsohn.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mendelsohn, R., Balick, M.J. The value of undiscovered pharmaceuticals in tropical forests. Econ Bot 49, 223–228 (1995). https://doi.org/10.1007/BF02862929

Download citation

Key Words

  • Pharmaceuticals
  • tropical forests
  • conservation
  • valuation